HBsAg Antibody - BSA Free Summary
| Immunogen |
Hepatitis B subtypes ad and ay |
| Specificity |
This product is specific for Hepatitis B surface antigen, recognizing subtypes ad and ay. Hepatitis B virus is a major causative agent of acute and chronic liver disease in humans. Hepatitis B surface antigen (HBsAg) is a protein component of the viral envelope, which is expressed predominantly in the cytoplasm of infected hepatocytes. |
| Isotype |
IgG |
| Clonality |
Polyclonal |
| Host |
Rabbit |
| Gene |
S |
| Purity |
Protein A purified |
| Innovator's Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase. |
Applications/Dilutions
| Dilutions |
- ELISA 1:10000
- Immunohistochemistry 1:10-1:500
- Immunohistochemistry-Frozen
- Immunohistochemistry-Paraffin 1:10-1:500
- Western Blot 1:1000-1:3000
|
| Publications |
Read Publications using
NB100-62652 in the following applications:
|
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer |
PBS |
| Preservative |
0.1% Sodium Azide |
| Concentration |
4.0 mg/ml |
| Purity |
Protein A purified |
Alternate Names for HBsAg Antibody - BSA Free
Background
Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are
guaranteed for 1 year from date of receipt.
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Video Protocols
FAQs for HBsAg Antibody (NB100-62652). (Showing 1 - 2 of 2 FAQs).
-
Our customer would like to know if NB100-62652 would recognize pre-S1 protein. If it is confirmed that this HBsAg antibody would bind to pre-S1, would you please help check if any HBsAg antibody provided would NOT recognize pre-S1?
- The HBV surface protein antigens (HBsAg) are comprised of three carboxyl co terminal HBs proteins termed large (LHBs), middle (MHBs) and small (SHBs, also called major) protein. LHBs and MHBs also share the highly hydrophobic, repetitive, membrane spanning S domain. In addition, LHBs has a 119 amino acid region called preS1. Now, all of our HBsAg antibodies are generated against native HBsAg molecule from various subtypes and I do not see any antibody which would not recognize pre-S1.
-
What is the immunogen used to generate this antibody?
- The immunogen was the whole organism, and we don't have any epitope information available. Since this antibody NB100-62652 (HBsAg Antibody) is a polyclonal one, I anticipate that the surface of HBsAg will be covered by the IgG molecules.
Secondary Antibodies
| |
Isotype Controls
|
Additional HBsAg Products
Research Areas for HBsAg Antibody (NB100-62652)
Find related products by research area.
|
Blogs on HBsAg
![Western Blot: HBsAg Antibody [NB100-62652] - HepAD38 cells were treated with DFMO (50 uM, 100 uM), and the HBV core-associated DNA was extracted 3 days later and measured by Southern blot (upper panel). The levels of HBc and HBs were measured by Western blotting, and capsids levels were determined using a Native gel assay (lower panel). Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fcimb.2020.00158/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HBsAg-Antibody-Western-Blot-NB100-62652-img0001.jpg "Western Blot: HBsAg Antibody [NB100-62652] - HepAD38 cells were treated with DFMO (50 uM, 100 uM), and the HBV core-associated DNA was extracted 3 days later and measured by Southern blot (upper panel). The levels of HBc and HBs were measured by Western blotting, and capsids levels were determined using a Native gel assay (lower panel). Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fcimb.2020.00158/full), licensed under a CC-BY license.")
![Western Blot: HBsAg Antibody [NB100-62652] - DFMO decreases the HBV core-associated DNA & the HBc protein levels. (A) Determination of cytotoxicity of HepAD38 & HepG2.2.15 cells treated DFMO measured by the MTS assay. (B) HepAD38 cells were treated with DFMO (50 μM, 100 μM), & the HBV core-associated DNA was extracted 3 days later & measured by Southern blot (upper panel). The levels of HBc & HBs were measured by Western blotting, & capsids levels were determined using a Native gel assay (lower panel) as described above. (C) The levels of HBsAg in supernatant were measured by ELISA assay as described above. (D) HBV 3.5kb RNA levels were measured by real-time RT-PCR. (E) & (F) HepG2.2.15 cells treated with DFMO (50, 100 μM) for 3 days, then the levels of intracellular HBV DNA or HBsAg levels in the supernatant were detected by real-time PCR (E) or ELISA assay (F). (G) DFMO decreased the infection capacity of the HBV particles. HepAD38 cells in the absence of tetracycline were treated with DSMO or DFMO with indicated concentration for 3 days, & the HBV viral particles were then collected & added to the HepG2-NTCP cells. Five days later, the cytoplasmic viral DNA were extracted & measured by real-time PCR. RC, relaxed circular; DL, double stranded linear; SS, single stranded. Experiments were performed in triplicate, & data are represented as means ± SD. Statistical significance was determined by one-way ANOVA with the Tukey post-hoc test (*p < 0.05; ns, not significant). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32373551), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-62652_rabbit-polyclonal-hbsag-antibody-31020241553746.jpg "Western Blot: HBsAg Antibody [NB100-62652] - DFMO decreases the HBV core-associated DNA & the HBc protein levels. (A) Determination of cytotoxicity of HepAD38 & HepG2.2.15 cells treated DFMO measured by the MTS assay. (B) HepAD38 cells were treated with DFMO (50 μM, 100 μM), & the HBV core-associated DNA was extracted 3 days later & measured by Southern blot (upper panel). The levels of HBc & HBs were measured by Western blotting, & capsids levels were determined using a Native gel assay (lower panel) as described above. (C) The levels of HBsAg in supernatant were measured by ELISA assay as described above. (D) HBV 3.5kb RNA levels were measured by real-time RT-PCR. (E) & (F) HepG2.2.15 cells treated with DFMO (50, 100 μM) for 3 days, then the levels of intracellular HBV DNA or HBsAg levels in the supernatant were detected by real-time PCR (E) or ELISA assay (F). (G) DFMO decreased the infection capacity of the HBV particles. HepAD38 cells in the absence of tetracycline were treated with DSMO or DFMO with indicated concentration for 3 days, & the HBV viral particles were then collected & added to the HepG2-NTCP cells. Five days later, the cytoplasmic viral DNA were extracted & measured by real-time PCR. RC, relaxed circular; DL, double stranded linear; SS, single stranded. Experiments were performed in triplicate, & data are represented as means ± SD. Statistical significance was determined by one-way ANOVA with the Tukey post-hoc test (*p < 0.05; ns, not significant). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32373551), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")